Previous 10 | Next 10 |
Radius Health (RDUS +3.3%) as 10% owner, Rubric Capital Management LP bought ~462.24K shares at $6.77 - $7.08 for a total transaction value of ~$3.2M. A quick look at the company's ownership structure: For further details see: Radius Health up ~4% as owner buys ...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. U.S. stocks finished higher on Friday to close out one of the best weeks since February. Investors took in a consumer price index report that...
Morgan Stanley has downgraded Radius Health (NASDAQ:RDUS) to underweight from equal-weight given a late-stage study on its abaloparatide patch for osteoporosis missed its primary endpoint. The firm cut its price target to $7 from $18 (~8% downside based on yesterday's close). Analyst Vikram P...
Radius Health (NASDAQ:RDUS) has stretched the recent losses to the fifth straight session as the investors come to terms with its failure to reach the primary endpoint in the Phase 3 trial for the abalo-TDS patch in postmenopausal women with osteoporosis. The positive late-stage data fro...
Traders had their eyes on Capitol Hill Wednesday. Along with a highly publicized appearance by heavy hitters from the crypto space, Instagram's top executive testified before lawmakers. This gave a lift to Meta (NASDAQ:FB), Snap (NYSE:SNAP) and Twitter (NYSE:TWTR). Roku (NASDAQ:ROKU) represen...
The stock of Radius Health (NASDAQ: RDUS) is tumbling today after the company presented follow-up data for its experimental breast cancer treatment. Investors disappointed with the biopharmaceutical company's update pushed the stock 44.3% lower as of 12:44 p.m. ET on Wednesday. ...
Shares of Radius Health (RDUS -44.9%) have continued to fall in afternoon trading after the company this morning said a late-stage trial of its abaloparatide transdermal system missed its primary endpoint. The trial was designed to show non-inferiority between Abalo-TDS and Tymlos (abaloparat...
Gainers: Insignia Systems (NASDAQ:ISIG) +106%. Energy Focus (NASDAQ:EFOI) +65%. Virpax (NASDAQ:VRPX) +26%. Aziyo (NASDAQ:AZYO) +26%. Digital World Acquisition (NASDAQ:DWACU) +20%. Digital World Acquisition (NASDAQ:DWAC) +20%. RLX Technology (NYSE:RLX) +20%. The Lovesac (NASDAQ:LOVE) +19%. Pho...
Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis (NYSE:STXS) +8%. Losers: Radius Health (NASDAQ:RDUS) -43%, Ensysce Biosciences (NASDAQ...
Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine therapy in overall population and estrogen receptor mutation (mESR1) population In the ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 54.4% to $0.4264 on volume of 158,036,142 shares Versus Systems Inc. (VS) rose 73.5% to $2.29 on volume of 40,036,424 shares Tesla Inc. (TSLA) rose 5.3% to $220.97 on volume of 32,375,487 shar...
Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the third quarter of fiscal 2024 ended May 31, 2024. ...